Literature DB >> 1977349

Prostaglandins and the release of the adrenergic transmitter.

K U Malik1, E Sehic.   

Abstract

Prostaglandins (PG) are synthesized from arachidonic acid, which is deesterified from tissue lipids in response to various stimuli including adrenergic transmitter, consequent to activation of one or more lipase(s). The profile of arachidonic acid metabolites generated in response to sympathetic nerve stimulation or administration of norepinephrine (NE) may vary in different tissues. For example, in the kidney and spleen, PGE2, is the major and PGI2 and PGF2 alpha the minor products; whereas in the heart and blood vessels, PGI2 is the principal product of arachidonic acid generated in response to sympathetic nerve stimulation. PGE2 and PGI2 inhibit release of NE and/or the postjunctional actions of this neurotransmitter in several tissues. These observations and the findings that inhibitors of cyclooxygenase enhance NE release and the response of effector organs to nerve stimulation suggest that PGs act as physiological modulators of adrenergic transmission. The mechanism by which PGs modulate release of the adrenergic transmitter has not yet been established. NE appears to be released from sympathetic fibers during depolarization by influx of Na+, which is associated with entry of Ca++ through omega-conotoxin-sensitive Ca++ channels that are distinct from those in the vascular smooth muscle, which are sensitive to nifedipine. Ouabain in low external K+ activates the former, whereas external Na+ depletion activates the latter type of Ca++ channels in the nerve fiber and promotes release of NE. PGs (PGE2) may inhibit release of NE from nerve fibers by interfering with the availability of Ca++ through these Ca++ channels or promoting efflux of Ca++ from the nerve terminal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977349     DOI: 10.1111/j.1749-6632.1990.tb31996.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  18 in total

1.  Inhibition of noradrenaline release in the rat vena cava via prostanoid receptors of the EP3-subtype.

Authors:  G Molderings; B Malinowska; E Schlicker
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

Review 2.  Minireview: The value of looking backward: the essential role of the hindbrain in counterregulatory responses to glucose deficit.

Authors:  Sue Ritter; Ai-Jun Li; Qing Wang; Thu T Dinh
Journal:  Endocrinology       Date:  2011-08-30       Impact factor: 4.736

3.  Inhibition of purinergic transmission by prostaglandin E1 and E2 in the guinea-pig vas deferens: an electrophysiological study.

Authors:  J A Brock; T C Cunnane
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Epoprostenol treatment of acute pulmonary hypertension is associated with a paradoxical decrease in right ventricular contractility.

Authors:  Steffen Rex; Carlo Missant; Patrick Segers; Rolf Rossaint; Patrick F Wouters
Journal:  Intensive Care Med       Date:  2007-08-21       Impact factor: 17.440

5.  In vitro activation of cyclo-oxygenase in the rabbit carotid body: effect of its blockade on [3H]catecholamine release.

Authors:  A Gómez-Niño; L Almaraz; C González
Journal:  J Physiol       Date:  1994-04-15       Impact factor: 5.182

6.  Evidence that M1 muscarinic receptors enhance noradrenaline release in mouse atria by activating protein kinase C.

Authors:  M Costa; M Barrington; H Majewski
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

7.  Thermoeffector neuronal pathways in fever: a study in rats showing a new role of the locus coeruleus.

Authors:  Maria C Almeida; Alexandre A Steiner; Norberto C Coimbra; Luiz G S Branco
Journal:  J Physiol       Date:  2004-05-14       Impact factor: 5.182

8.  Prostanoid receptors of the EP3 subtype mediate the inhibitory effect of prostaglandin E2 on noradrenaline release in the mouse brain cortex.

Authors:  H J Exner; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

9.  Blunted sympathetic vasoconstriction in contracting skeletal muscle of healthy humans: is nitric oxide obligatory?

Authors:  Frank A Dinenno; Michael J Joyner
Journal:  J Physiol       Date:  2003-08-29       Impact factor: 5.182

10.  Modulation of noradrenaline release from the sympathetic nerves of the human saphenous vein and pulmonary artery by presynaptic EP3- and DP-receptors.

Authors:  G J Molderings; E Colling; J Likungu; J Jakschik; M Göthert
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.